Literature DB >> 3858060

Systemic isotretinoin treatment of oral and cutaneous lichen planus.

T Y Woo.   

Abstract

Lichen planus of the skin and mucous membranes may be disabling. Severe pruritus or bullous lesions may be incapacitating when they occur while erosive oral lesions may be extremely painful. Various treatment modalities have been attempted including corticosteroids (parenteral, intralesional, and topical) and photochemotherapy. Recent successful therapeutic trials of topical retinoic acid and oral etretinate have been completed. Two patients with cutaneous and severe erosive oral lichen planus unresponsive to conventional therapies responded to a trial of oral isotretinoin with prompt and successful remission of cutaneous and oral lesions. This suggests that systemic isotretinoin may have a unique position in the treatment of mucous membrane lichen planus that is refractory to conventional therapies.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3858060

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  5 in total

1.  Purplish, pruritic papules on the limbs.

Authors:  J C Cather; M A Menter
Journal:  Proc (Bayl Univ Med Cent)       Date:  2001-10

Review 2.  Mouthwashes in the treatment of oral disease.

Authors:  D J Zegarelli
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

Review 3.  The retinoids. A review of their clinical pharmacology and therapeutic use.

Authors:  C E Orfanos; R Ehlert; H Gollnick
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

4.  To Study the Prevalence of Premalignancies in Teenagers having Betel, Gutkha, Khaini, Tobacco Chewing, Beedi and Ganja Smoking Habit and Their Association with Social Class and Education Status.

Authors:  Vinay Kumar Srivastava
Journal:  Int J Clin Pediatr Dent       Date:  2014-08-29

5.  Oral isotretinoin for the treatment of dermatologic conditions other than acne: a systematic review and discussion of future directions.

Authors:  Sherman Chu; Lauren Michelle; Chloe Ekelem; Calvin T Sung; Nathan Rojek; Natasha A Mesinkovska
Journal:  Arch Dermatol Res       Date:  2020-11-05       Impact factor: 3.017

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.